Drug and Alcohol Dependence
Volume 111, Issue 1 , Pages 50-57 , 1 September 2010

Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women

  • Eugenia Oviedo-Joekes

      Affiliations

    • School of Population and Public Health, University of British Columbia, 5804 Fairview Ave, Vancouver, BC, Canada V6T 1Z3
    • Centre for Health Evaluation & Outcome Sciences, Providence Health Care, 620-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    • Corresponding Author InformationCorresponding author at: St. Paul's Hospital, 620-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6. Tel.: +1 604 682 2344x62973; fax: +1 604 806 8210.
    • ,
  • Daphne Guh

      Affiliations

    • Centre for Health Evaluation & Outcome Sciences, Providence Health Care, 620-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    • ,
  • Suzanne Brissette

      Affiliations

    • Centre Hospitalier de l’Université de Montréal, Hôpital Saint-Luc, CHUM Montréal, QC, Canada H2X 3J4
    • ,
  • Kirsten Marchand

      Affiliations

    • Centre for Health Evaluation & Outcome Sciences, Providence Health Care, 620-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    • ,
  • David Marsh

      Affiliations

    • School of Population and Public Health, University of British Columbia, 5804 Fairview Ave, Vancouver, BC, Canada V6T 1Z3
    • Centre for Health Evaluation & Outcome Sciences, Providence Health Care, 620-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    • Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall Vancouver, BC, Canada V6T 2A1
    • Vancouver Coastal Health & Providence Health Care, 620-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    • Centre for Addiction Treatment BC, University of Victoria, 2300 McKenzie Ave, Victoria, BC, Canada V8P 5C2
    • ,
  • Jill Chettiar

      Affiliations

    • Centre for Health Evaluation & Outcome Sciences, Providence Health Care, 620-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    • ,
  • Bohdan Nosyk

      Affiliations

    • Centre for Health Evaluation & Outcome Sciences, Providence Health Care, 620-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    • ,
  • Michael Krausz

      Affiliations

    • Centre for Health Evaluation & Outcome Sciences, Providence Health Care, 620-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    • Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall Vancouver, BC, Canada V6T 2A1
    • ,
  • Aslam Anis

      Affiliations

    • School of Population and Public Health, University of British Columbia, 5804 Fairview Ave, Vancouver, BC, Canada V6T 1Z3
    • Centre for Health Evaluation & Outcome Sciences, Providence Health Care, 620-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    • ,
  • Martin T. Schechter

      Affiliations

    • School of Population and Public Health, University of British Columbia, 5804 Fairview Ave, Vancouver, BC, Canada V6T 1Z3
    • Centre for Health Evaluation & Outcome Sciences, Providence Health Care, 620-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6

Received 22 October 2009 ,Revised 16 March 2010 ,Accepted 16 March 2010.

References 

  1. Acharyya S, Zhang H. Assessing sex differences on treatment effectiveness from the drug abuse treatment outcome study DATOS. Am. J. Drug Alcohol Abuse. 2003;29:415–444
  2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders DSM-IV. American Psychiatric Association; 1994;
  3. Anderson JF, Warren LD. Client retention in the British Columbia Methadone Program, 1996–1999. Can. J. Public Health. 2004;95:104–109
  4. Arfken CL, Klein C, di Menza S, Schuster CR. Gender differences in problem severity at assessment and treatment retention. J. Subst. Abuse Treat. 2001;20:53–57
  5. Bennett GA, Velleman RD, Barter G, Bradbury C. Gender differences in sharing injecting equipment by drug users in England. AIDS Care. 2000;12:77–87
  6. Booth RE, Corsi KF, Mikulich-Gilbertson SK. Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. Drug Alcohol Depend. 2004;74:177–185
  7. Brady KT, Randall CL. Gender differences in substance use disorders. Psychiatr. Clin. North Am. 1999;22:241–252
  8. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J. Clin. Epidemiol. 1998;51:1115–1128
  9. Brewer DD, Fleming CB, Haggerty KP, Catalano RF. Drug use predictors of partner violence in opiate-dependent women. Violence Vict. 1998;13:107–115
  10. Charney DA, Palacios-Boix J, Gill KJ. Sexual abuse and the outcome of addiction treatment. Am. J. Addict. 2007;16:93–100
  11. Chatham LR, Hiller ML, Rowan-Szal GA, Joe GW, Simpson DD. Gender differences at admission and follow-up in a sample of methadone maintenance clients. Subst. Use Misuse. 1999;34:1137–1165
  12. Covington SS. Women and addiction: a trauma-informed approach. J. Psychoactive Drugs Suppl. 2008;5:377–385
  13. Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998;51:253–263discussion 267–268
  14. De Wilde J, Broekaert E, Rosseel Y, Delespaul P, Soyez V. The role of gender differences and other client characteristics in the prevalence of DSM-IV affective disorders among a European therapeutic community population. Psychiatr. Q. 2007;78:39–51
  15. Des Jarlais DC, Arasteh K, Perlis T, Hagan H, Abdul-Quader A, Heckathorn DD, et al. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS. 2007;21:231–235
  16. Erickson PG, Butters J, Mcgillicuddy P, Hallgren A. Crack and prostitution: gender, myths, and experiences. J. Drug Issues. 2000;30:767–788
  17. Fattore L, Altea S, Fratta W. Sex differences in drug addiction: a review of animal and human studies. Womens Health Lond. Engl. 2008;4:51–65
  18. Fischer B, Cruz MF, Rehm J. Illicit opioid use and its key characteristics: a select overview and evidence from a Canadian multisite cohort of illicit opioid users OPICAN. Can. J. Psychiatry. 2006;51:624–634
  19. Green CA. Gender and use of substance abuse treatment services. Alcohol Res. Health. 2006;29:55–62
  20. Greenfield SF, Brooks AJ, Gordon SM, Green CA, Kropp F, McHugh RK, et al. Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend. 2007;86:1–21
  21. Grella CE. From generic to gender-responsive treatment: changes in social policies, treatment services, and outcomes of women in substance abuse treatment. J. Psychoactive Drugs Suppl. 2008;5:327–343
  22. Grella CE, Karno MP, Warda US, Niv N, Moore AA. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict. Behav. 2009;
  23. Gschwend P, Rehm J, Eschmann S, Uchtenhagen A. Heroin-assisted treatment of opioid addicts in Switzerland from 1994–2001—utilisation and characteristics of admissions and discharges. Gesundheitswesen. 2003;65:75–80
  24. Haasen C, Vertheim U, Degkwitz P, Kuhn S, Ilse J, Lachmann A, et al. The German Model Project for Heroin Assisted Treatment of Opioid Dependent Patients. A Multicentric, Randomised, Controlled Treatment Study. Germany: Centre for Interdisciplinary Addiction Research of Hamburg University ZIS; 2006;
  25. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br. J. Psychiatry. 2007;191:55–62
  26. Hartel DM, Schoenbaum EE, Lo Y, Klein RS. Gender differences in illicit substance use among middle-aged drug users with or at risk for HIV infection. Clin. Infect. Dis. 2006;43:525–531
  27. Heading CE. Gender issues and the pharmacotherapy of substance abuse. IDrugs. 2008;11:428–432
  28. Health Canada . Best Practices in Methadone Maintenance Treatment. ON, Canada: Minister of Public Works and Government Services Canada; 2002;
  29. Hser YI, Huang Y, Teruya C, Anglin MD. Gender differences in treatment outcomes over a three-year period: a path model analysis. J. Drug Issues. 2004;34:419–440
  30. Hser YI, Jhosi V, Maglione M, Chou CP, Anglin MD. Effects of program and patients characteristics on retention of drug treatment patients. Eval. Program Plann. 2001;24:331–341
  31. Joe GW, Simpson DD, Broome KM. Retention and patient engagement models for different treatment modalities in DATOS. Drug Alcohol Depend. 1999;57:113–125
  32. Jones HE, Fitzgerald H, Johnson RE. Males and females differ in response to opioid agonist medications. Am. J. Addict. 2005;14:223–233
  33. Kerr T, Marsh D, Li K, Montaner J, Wood E. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug Alcohol Depend. 2005;80:329–335
  34. Kokkevi A, Hartgers C. EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur. Addict. Res. 1995;1:208–210
  35. Liu N, Zhou D, Li B, Ma Y, Hu X. Gender related effects of heroin abuse on the simple reaction time task. Addict. Behav. 2006;31:187–190
  36. Lynch WJ, Roth ME, Carroll ME. Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology (Berl.). 2002;164:121–137
  37. Magura S, Nwakeze PC, Demsky SY. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction. 1998;93:51–60
  38. March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J. Subst. Abuse Treat. 2006;31:203–211
  39. Marsden J, Gossop M, Stewart D, Best D, Farrell M, Lehmann P, et al. The Maudsley Addiction Profile MAP: a brief instrument for assessing treatment outcome. Addiction. 1998;93:1857–1867
  40. McLellan TA, Cacciola JC, Alterman AI, Rikoon SH, Carise D. The Addiction Severity Index at 25: origins, contributions and transitions. Am. J. Addict. 2006;15:113–124
  41. Metrebian N, Shanahan W, Stimson GV, Small C, Lee M, Mtutu V, et al. Prescribing drug of choice to opiate dependent drug users: a comparison of clients receiving heroin with those receiving injectable methadone at a West London drug clinic. Drug Alcohol Rev. 2001;20:267–276
  42. Mulvaney FD, Brown LS, Alterman AI, Sage RE, Cnaan A, Cacciola J, et al. Methadone-maintenance outcomes for Hispanic and African-American men and women. Drug Alcohol Depend. 1999;54:11–18
  43. Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N. Engl. J. Med. 2009;361:777–786
  44. Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Nosyk B, Krausz M, et al. Double-blind Injectable Hydromorphone versus Diacetylmorphine for the treatment of opioid dependence. Journal of Substance Abuse Treatment. 2010;38:408–411
  45. Oviedo-Joekes E, Nosyk B, Brissette S, Chettiar J, Schneeberger P, Marsh DC, et al. The North American Opiate Medication Initiative NAOMI: profile of participants in North America's first trial of heroin-assisted treatment. J. Urban Health. 2008;85:812–825
  46. Oviedo-Joekes E, Nosyk B, Marsh D, Guh D, Brissette S, Gartry C, et al. Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: rationale and design of the NAOMI study. Clin. Trials. 2009;6:261–271
  47. Peles E, Adelson M. Gender differences and pregnant women in a methadone maintenance treatment MMT clinic. J. Addict. Dis. 2006;25:39–45
  48. Perreault M, Rousseau M, Mercier C, Lauzon P, Gagnon C, Cote P. Accessibility to methadone substitution treatment: the role of a low-threshold program. Can. J. Public Health. 2003;94:197–200
  49. Petry NM, Bickel WK. Gender differences in hostility of opioid-dependent outpatients: role in early treatment termination. Drug Alcohol Depend. 2000;58:27–33
  50. Powis B, Griffiths P, Gossop M, Strang J. The differences between male and female drug users: community samples of heroin and cocaine users compared. Subst. Use Misuse. 1996;31:529–543
  51. Puigdollers E, Domingo-Salvany A, Brugal MT, Torrens M, Alvaros J, Castillo C, et al. Characteristics of heroin addicts entering methadone maintenance treatment: quality of life and gender. Subst. Use Misuse. 2004;39:1353–1368
  52. Rehm J, Frick U, Hartwig C, Gutzwiller F, Gschwend P, Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994–2000. Drug Alcohol Depend. 2005;79:137–143
  53. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet. 2001;358:1417–1423
  54. Ribeaud D. Long-term impacts of the Swiss heroin prescription trials on crime of treated heroin users. J. Drug Issues. 2004;34:163–194
  55. Room R. Heroin maintenance and attraction to treatment. Eur. J. Public Health. 2002;12:234–235
  56. Roth ME, Cosgrove KP, Carroll ME. Sex differences in the vulnerability to drug abuse: a review of preclinical studies. Neurosci. Biobehav. Rev. 2004;28:533–546
  57. Rounsaville BJ, Tierney T, Crits-Christoph K, Weissman MM, Kleber HD. Predictors of outcome in treatment of opiate addicts: evidence for the multidimensional nature of addicts’ problems. Compr. Psychiatry. 1982;23:462–478
  58. Simpson DD, Joe GW, Rowan-Szal GA. Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend. 1997;47:227–235
  59. Spitzer DL. Engendering health disparities. Can. J. Public Health. 2005;96(Suppl. 2):S78–S96
  60. Stewart D, Gossop M, Marsden J, Kidd T, Treacy S. Similarities in outcomes for men and women after drug misuse treatment: results from the National Treatment Outcome Research Study NTORS. Drug Alcohol Rev. 2003;22:35–41
  61. Tetrault JM, Desai RA, Becker WC, Fiellin DA, Concato J, Sullivan LE. Gender and non-medical use of prescription opioids: results from a national US survey. Addiction. 2008;103:258–268
  62. Uphold CR, Mkanta WN. Review: use of health care services among persons living with HIV infection: state of the science and future directions. AIDS Patient Care STDS. 2005;19:473–485
  63. van den Brink W, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003;327:310
  64. van der Zanden BP, Dijkgraaf MG, Blanken P, de Borgie CA, van Ree JM, van den Brink W. Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population. Drug Alcohol Depend. 2006;82:111–118
  65. Van Etten ML, Neumark YD, Anthony JC. Male–female differences in the earliest stages of drug involvement. Addiction. 1999;94:1413–1419
  66. Wechsberg WM, Craddock SG, Hubbard RL. How are women who enter substance abuse treatment different than men?: a gender comparison from the Drub Abuse Treatment Outcome Study DATOS. Drugs Soc. 1998;13:97–115
  67. Weiss SR, Kung HC, Pearson JL. Emerging issues in gender and ethnic differences in substance abuse and treatment. Curr. Womens Health Rep. 2003;3:245–253
  68. Wetherington CL. Sex–gender differences in drug abuse: a shift in the burden of proof?. Exp. Clin. Psychopharmacol. 2007;15:411–417
  69. Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003;98:673–684
  70. Zilberman M, Tavares H, el-Guebaly N. Gender similarities and differences: the prevalence and course of alcohol- and other substance-related disorders. J. Addict. Dis. 2003;22:61–74
  71. Zilberman ML, Tavares H, Hodgins DC, el-Guebaly N. The impact of gender, depression, and personality on craving. J. Addict. Dis. 2007;26:79–84

PII: S0376-8716(10)00137-7

doi: 10.1016/j.drugalcdep.2010.03.016

Drug and Alcohol Dependence
Volume 111, Issue 1 , Pages 50-57 , 1 September 2010

Article Tools